Gliomas
Reports Summarize Gliomas Research from University of Chicago, Brain Tumor Center
Published in Drug Week, January 21st, 2011
2011 JAN 21 -- Investigators publish new data in the report 'Challenges in clinical design of immunotherapy trials for malignant glioma.' According to recent research from the United States, "Glioblastoma multiforme (GBM) is the most common and lethal primary malignant brain tumor. The traditional treatments for GBM, including surgery, radiation, and chemotherapy, only modestly improve patient survival."
"Therefore, immunotherapy has emerged as a novel therapeutic modality. Immunotherapeutic strategies exploit the immune system's ability to recognize and mount a specific response against tumor cells, but not normal cells. Current immunotherapeutic...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2011-01-21)
More Articles from Drug Week
- Lifespan
Where Mrsa Colonizes on the Human Body - Stem Cell Research
Uthealth Studies Cord Blood Stem Cells for Pediatric Traumatic Brain Injury - Cell Proliferation
University of Texas Health Science Center at Houston, Institute of Molecular Medicine for the Prevention of Human Diseases Reports Research in Cell Proliferation - Dystonia
University of New South Wales Details Research in Dystonia - Hormones
University of Massachusetts Reports Research in Hormones - Lung Cancer
University of Manchester Details Research in Lung Cancer - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
